Compare RBB & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBB | ENTA |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.0M | 371.6M |
| IPO Year | 2017 | 2012 |
| Metric | RBB | ENTA |
|---|---|---|
| Price | $26.56 | $12.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $22.00 | $20.40 |
| AVG Volume (30 Days) | ★ 203.3K | 175.4K |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | 24.49 | ★ 29.93 |
| EPS | ★ 0.66 | N/A |
| Revenue | $5,167,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $20.50 | $7.76 |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $39.82 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $16.74 | $6.45 |
| 52 Week High | $28.24 | $17.15 |
| Indicator | RBB | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 43.94 |
| Support Level | $20.11 | $11.92 |
| Resistance Level | $28.22 | $13.98 |
| Average True Range (ATR) | 0.80 | 0.73 |
| MACD | -0.20 | -0.14 |
| Stochastic Oscillator | 34.06 | 19.83 |
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.